The trial will enroll 3,000 healthy participants in the United States and will assess the safety and effectiveness of two doses of the company's vaccine candidate, mRNA-1273, given 28 days apart. Moderna has submitted applications seeking emergency use authorisation (EUA) in the United States and EU after full results from a late-stage study showed the vaccine was 94.1% effective in adults with no serious safety concerns. Rival Pfizer/BioNTech have also sought EUA after their coronavirus vaccine's two-dose regimen proved 95% effective against COVID-19 and had no major safety issues. A similar meeting of advisers to the FDA is scheduled for Dec. 17 to discuss Moderna's vaccine. Pfizer is also studying its vaccine candidate in participants as young as 12.

Source: bd News24 December 10, 2020 13:30 UTC